对冠状动脉疾病的精准医学方法:以哈普特蛋白表型为导向的风险评估
Zhengxin He1, Hong Liu2, Keran Jia1
1Laboratory of Basic Medicine, Bethune International Peace Hospital, Shijiazhuang, Hebei 050082, P.R. China.
Molecular medicine reports
|March 13, 2026
概括
黑球蛋白 (HP) 水平和 Hp2-2 基因型与中国人的冠状动脉疾病 (CAD) 风险增加有关. 基因型特定的HP评估可以改善CAD风险评估.
科学领域:
- 遗传学和心血管疾病
- 生物标志物发现发现
- 人口健康 人口健康
背景情况:
- 黑球蛋白 (HP) 多态性影响抗氧化能力和冠状动脉疾病 (CAD) 易感性,已知有种族差异.
- 在中国人群中关于CAD风险的HP表型和血清度的研究有限.
研究的目的:
- 调查中国队列中哈普特蛋白 (HP) 参数 (基因型和血清度) 与冠状动脉疾病 (CAD) 风险之间的关联.
- 探索HP参数与心脏功能之间的关系,包括左心室喷射率 (LVEF) 和疾病严重程度.
主要方法:
- 一项基于医院的研究,涉及230名CAD患者,83名血管学定义的对照者和192名健康对照者.
- 通过免疫度测定测量血清HP度;通过RT-qPCR和PAGE确定HP基因型.
- 采用多变量逻辑回归和基因型分层分析来确定CAD预测因子,并评估HP与心脏功能和疾病严重程度的关联.
主要成果:
- 与健康对照组相比,在CAD患者中观察到更高的Hp2-2基因型流行率和更高的基因型特异性血清HP度.
- 血清HP度,高血压,甘油三水平和HP2-2表型是独立的CAD风险因素;高脂胆固醇具有保护作用.
- Hp1-1载体显示了HP水平和LVEF之间的反相关性,而Hp2-2载体显示了中度相关性. 在HP1-1患者中,HP水平与血管数量之间也有正相关性.
结论:
- 血清HP度是中国人群中强大的CAD风险生物标志物,其临床相关性因基因型而改变.
- 携带hp1-1的患者显示了高hp水平与心脏功能受损之间的强烈关联.
- 基因型分层HP评估可以在精准医学框架内增强CAD风险评估.
相关概念视频
01:29Pharmacogenomics: Identification of New Drug Targets
61
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61
01:26Coronary Artery Disease IV: Preventive Measures
793
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
793
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
611
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
611
01:30Coronary Artery Disease I: Introduction
1.4K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
83
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
01:27Coronary Artery Disease V: Interprofessional Care
359
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
359